KR910700067A - 항 hiv제 - Google Patents

항 hiv제

Info

Publication number
KR910700067A
KR910700067A KR1019900701982A KR900701982A KR910700067A KR 910700067 A KR910700067 A KR 910700067A KR 1019900701982 A KR1019900701982 A KR 1019900701982A KR 900701982 A KR900701982 A KR 900701982A KR 910700067 A KR910700067 A KR 910700067A
Authority
KR
South Korea
Prior art keywords
plasma protein
hiv agent
human
amino acid
chemically modified
Prior art date
Application number
KR1019900701982A
Other languages
English (en)
Other versions
KR0128098B1 (ko
Inventor
하지메 쯔누
마사오 다까미
겐지 미쯔모또
Original Assignee
나까야마 히사시
메이지 뉴교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나까야마 히사시, 메이지 뉴교 가부시끼가이샤 filed Critical 나까야마 히사시
Publication of KR910700067A publication Critical patent/KR910700067A/ko
Application granted granted Critical
Publication of KR0128098B1 publication Critical patent/KR0128098B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음.

Description

항 HIV제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 세포주 Molt-4/HIV와 Molt-4, clone no.8과의 혼합배양액에 최종농도 20㎍/㎖의 M-HSA 또는 50μ/㎖의 DS를 첨가하여 거대 세포 형성에 의해 생기는 세포 변성 치사를 지지하는 효과에 대하여 경시적으로 MIT앗세이를 사용하여 생세포수를 조사한 결과를 나타낸 그래프이다,
제2도-(A) 내지 제2도-(D)는 M-HSA. DS 존재하에서 세포주 Molt-4/HIV 와 Molt-4, clone no.8과를 혼합 배양한 때의 형태 변화를 배양 4일 째에 현미경으로 관찰한 스켓치를 나타낸다.

Claims (5)

  1. 혈장 단백질의 구성 아미노산 잔기의 아미노산 전하의 극성이 음으로 화학 수식된 화학 수식 단백질을 유효성분으로서 함유하는 항HIV제.
  2. 혈장 단백질의 구성 아미노산 잔기의 아미노기가 무수디카르복실산으로 화학 수식된 화학 수식 혈장 단백질을 유효성분으로서 함유하는 항HIV제.
  3. 무수 디카르복실산이 무수 말레인산 또는 무수 숙신산인 청구범위 2의 항HIV제.
  4. 혈장 단백질이 사람 유래 또는 소 유래의 것인 청구범위 1 또는 청구범위 2의 항HIV제.
  5. 혈장 단백질이 사람 혈청 알부민. 사람 면역 글로블린. 사람 트랜스페린, 사람 피브리노겐 및 소 혈청 알부민으로부터 이루어진 군에서 선택된 것인 청구범위 4의 항HIV제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900701982A 1989-01-09 1989-01-30 항hiv제 KR0128098B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP257489 1989-01-09
JP2574-1989 1989-01-09
JP2574/89 1989-01-09
JP1879089 1989-01-27
JP18790/89 1989-01-27
JP18790/1989 1989-01-27
PCT/JP1989/000094 WO1990007340A1 (en) 1989-01-09 1989-01-30 Anti-hiv agent

Publications (2)

Publication Number Publication Date
KR910700067A true KR910700067A (ko) 1991-03-13
KR0128098B1 KR0128098B1 (ko) 1998-04-04

Family

ID=26335984

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900701982A KR0128098B1 (ko) 1989-01-09 1989-01-30 항hiv제

Country Status (7)

Country Link
US (1) US5164486A (ko)
EP (1) EP0406416B1 (ko)
KR (1) KR0128098B1 (ko)
AU (1) AU636104B2 (ko)
DE (1) DE68912582T2 (ko)
OA (1) OA09308A (ko)
WO (1) WO1990007340A1 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9100434A (nl) * 1991-03-11 1992-10-01 Rijksuniversiteit Farmaceutische preparaten voor de bestrijding van virale infecties en immuundeficientieziekten, de bereiding en toepassing daarvan.
US5869457A (en) * 1991-03-11 1999-02-09 Rijksuniversiteit Te Groningen Modified proteins and their use for controlling viral infections
US5336782A (en) * 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
CA2113837A1 (en) * 1991-08-02 1993-02-18 Kenji Mizumoto Anti-hiv agent
IT1251702B (it) * 1991-10-16 1995-05-19 Mediolanum Farmaceutici Srl Complessi del ferro con la conalbumina e i suoi derivati
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤
US5985275A (en) * 1995-04-12 1999-11-16 New York Blood Center β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
US5952009A (en) * 1996-03-20 1999-09-14 New York Blood Center Methods for preventing the transmission of or treating patients infected with herpesvirus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE316928B (ko) * 1966-11-25 1969-11-03 Kabi Ab
JPS56147724A (en) * 1980-04-18 1981-11-16 Teijin Ltd Igm derivative and immunoglobulin preparation for intravenous injection containing said compound as effective component
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
US4863730A (en) * 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
AU598300B2 (en) * 1986-09-04 1990-06-21 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
FR2625902A3 (fr) * 1988-12-12 1989-07-21 Zagyansky Yuly Un nouveau moyen de lutte contre les virus (tels les virus du sida) et contre les bacteries avec les anticorps modifies par changement de charge

Also Published As

Publication number Publication date
US5164486A (en) 1992-11-17
AU636104B2 (en) 1993-04-22
DE68912582D1 (de) 1994-03-03
KR0128098B1 (ko) 1998-04-04
EP0406416A4 (en) 1991-11-21
OA09308A (en) 1992-09-15
EP0406416B1 (en) 1994-01-19
AU2937489A (en) 1990-08-01
WO1990007340A1 (en) 1990-07-12
DE68912582T2 (de) 1994-08-11
EP0406416A1 (en) 1991-01-09

Similar Documents

Publication Publication Date Title
DE69633228D1 (de) Botulinumtoxinderivate die periferishe sensorische afferende funktionen ändern können
IN178499B (ko)
NO993709D0 (no) Stabilisert blanding omfattende fibrinogen
MX9704767A (es) Inhibidores de la adhesion de fibronectina.
KR910700067A (ko) 항 hiv제
DK0383599T3 (da) Protein-anticancermiddel
ATE48142T1 (de) Blutprotein, verfahren zu seiner herstellung, antikoerper gegen dieses protein und dieses protein oder diese antikoerper enthaltende pharmazeutische zubereitungen.
Somers et al. Functional domains of proteoliaisin, the adhesive protein that orchestrates fertilization envelope assembly.
DE3476666D1 (en) Novel peptide, process for the preparation thereof and pharmaceutical composition containing said peptide
JPS56138188A (en) Novel amidine, manufacture, pharmaceutical composition containing same and application thereof
Yoder et al. Membrane specificity of Leuconostoc mesenteroides for the stereoisomeric forms of glycine and valine dipeptides
Aszalos et al. Effect of an interferon inhibitor on the antiproliferative signal of interferon-α
Head et al. Calcium-binding proteins from squid optic lobes
Okusu et al. Benjamin S. Weeks". Motoyoshi Nomizuº, Akira Otakaº, Christi A. Weston “
KR950023648A (ko) 생물학적 활성을 나타내는 폴리펩티드
RU94046405A (ru) Птг-соединения и содержащий их фармацевтический состав, способ получения желаемых полипептидов, нуклеотидная последовательность, бактериальный вектор экспрессии, бактериальные хозяйские клетки и составной белок

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110920

Year of fee payment: 15

EXPY Expiration of term